R&D Pipeline
Nektar Therapeutics has a targeted portfolio of novel therapeutics that target cytokine pathways and other mechanisms to selectively modulate the immune system and to advance the treatment of cancer, autoimmune disorders, and chronic inflammatory conditions.
Nektar is also engaged in a series of co-development and commercialization collaborations with pharmaceutical industry leaders and emerging biotech companies.
Therapeutic Area
Condition/Disease
Agents
Mechanism
Phase
Partner
Genitourinary Cancer
Locally Advanced or Metastatic Urothelial Carcinoma
Locally Advanced or Metastatic Urothelial Carcinoma
Agent(s)
NKTR-255 + Bavencio®
Mechanism
IL-15 Pathway Agonist + Anti-PD-L1
Partner
NCT#
NCT05327530
STUDY
JAVELIN Bladder Medley
Hematological Cancer
Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Solid Tumors
Metastatic Colorectal Cancer or Metastatic Head and Neck Cancer
Metastatic Colorectal Cancer or Metastatic Head and Neck Cancer
Autoimmune Disorders
Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Agent(s)
NKTR-358
Mechanism
IL-2 T Regulatory Cell Stimulator
Partner
NCT#
NCT04433585
STUDY
ISLAND-SLE
Autoimmune Disorders
Psoriasis
Psoriasis
Autoimmune Disorders
Atopic Dermatitis
Atopic Dermatitis
Immuno-Oncology
Autoimmune Disorders
Agent(s)
TNFR antibody
Mechanism
Bivalent Agonistic Antibody Targeting TNFR2
Partner
